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Role of group 1 CD1-restricted  
T cells in infectious disease
Sarah Siddiqui, Lavanya Visvabharathy and Chyung-Ru Wang*
Department of Microbiology and Immunology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
The evolutionarily conserved CD1 family of antigen-presenting molecules presents lipid 
antigens rather than peptide antigens to T cells. CD1 molecules, unlike classical MHC 
molecules, display limited polymorphism, making CD1-restricted lipid antigens attractive 
vaccine targets that could be recognized in a genetically diverse human population. Group 
1 CD1 (CD1a, CD1b, and CD1c)-restricted T cells have been implicated to play critical 
roles in a variety of autoimmune and infectious diseases. In this review, we summarize 
current knowledge and recent discoveries on the development of group 1 CD1-restricted 
T cells and their function in different infection models. In particular, we focus on (1) newly 
identified microbial and self-lipid antigens, (2) kinetics, phenotype, and unique properties 
of group 1 CD1-restricted T cells during infection, and (3) the similarities of group 1 
CD1-restricted T cells to the closely related group 2 CD1-restricted T cells.
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introduction
The CD1 gene family encodes several MHC class I-like antigen-presenting molecules, which are 
specialized to present lipid antigens to T cells. The lipid antigens presented by CD1 include a diverse 
array of lipids/glycolipids, ranging from foreign lipids unique to specific microorganisms to common 
mammalian self-lipids. Three major groups of CD1 isoforms have been identified in humans: group 
1 CD1 (CD1a, CD1b, and CD1c), group 2 CD1 (CD1d), and group 3 CD1 (CD1e) (1). Although 
homologs exist in the guinea pigs and other vertebrates, mice, and rats do not express group 1 CD1 
(2, 3), making the in vivo functional study of group 1 CD1-restricted T cells difficult until the recent 
development of small animal models (4–6). This review will outline group 1 CD1 antigen binding 
and presentation, newly identified group 1 CD1-restricted self- and microbial lipid antigens, and the 
interaction of group 1 CD1-expressing antigen-presenting cells (APCs) with their corresponding T 
cell subsets. Additionally, the development and function of group 1 CD1-restricted T cells will be 
discussed, with special emphasis placed on small animal models, dynamics of these T cells during 
Mycobacterium tuberculosis (Mtb) infection, and the contribution of microbial antigen-specific and 
autoreactive group 1 CD1-restricted T cells to host defense against infection. Finally, the expansion 
of our knowledge of group 1 CD1-restricted T cell responses allows for their comparison with a more 
well-studied and related subset of T cells, the group 2 CD1-restricted NKT cells. The last section will 
focus on comparing and contrasting the properties of group 1 vs. group 2 CD1-restricted T cells.
expression of Group 1 CD1 Molecules
Unlike MHC class Ia, which is expressed on all nucleated cells, the expression of group 1 CD1 is 
mainly limited to APCs and double-positive (CD4+CD8+) cortical thymocytes (1). CD1a molecules 
are highly expressed on skin resident DCs, or Langerhans cells (7). CD1b is most highly expressed on 
June 2015 | Volume 6 | Article 3372
Siddiqui et al. Group 1 CD1-restricted T cells in infectious disease
Frontiers in Immunology | www.frontiersin.org
a subset of migrating lymph dendritic cells and myeloid-derived 
dendritic cells (8). CD1c is the most ubiquitously expressed group 
1 CD1 molecule, being found on monocyte-derived DCs, B cells, 
and Langerhans cells under steady-state conditions (9, 10). CD1e 
is the only CD1 isoform that is not expressed on the surface of 
APCs (11). In immature DCs, CD1e is mainly localized in the Golgi 
apparatus and in mature DCs, it is detected in late endosomes, 
where it is cleaved into a functional soluble form (12). CD1e is 
thought to facilitate the processing and presentation of certain 
lipid antigens presented by CD1b (13).
Group 1 CD1 expression can also be regulated by various 
cytokines. Treatment of activated monocytes with GM-CSF 
and IL-4, which leads to dendritic cell differentiation, results in 
increased levels of group 1 CD1 expression (14). Group 1 CD1 
expression is also altered in different disease models, implying a 
role for group 1 CD1-restricted T cells in the pathology and/or 
repression of the disease. Patients with the tuberculoid form of 
leprosy, a clinical pattern associated with active cellular immunity 
toward Mycobacterium leprae, show induction of CD1a, CD1b, 
and CD1c on DCs in dermal granulomas (15). Increased CD1b 
and CD1c expression has also been reported in the human skin 
upon Borrelia burgdorferi infection (16). CD1a expression on 
Langerhans cells has been correlated with a variety of autoimmune 
skin diseases, including atopic eczema (7, 17, 18) and psoriasis 
(19, 20). In addition, some leukemias and lymphomas express 
one or all group 1 CD1 molecules (21). One recent study showed 
that CD1c+ B cell leukemia precursors are efficiently targeted and 
lysed by CD1c autoreactive T cells, highlighting a role of group 1 
CD1-restrcited T cells in anti-tumor immunity (22).
Binding and Presentation of Lipid Antigens 
by Group 1 CD1 Molecules
Group 1 CD1 isoforms have structurally diverse antigen-binding 
grooves that allow them to bind very different lipid classes. Group 1 
CD1 isoforms also differ in their stability when lipids are bound in 
the binding groove vs. when the groove lies empty, which is consist-
ent with their intracellular trafficking patterns and consequently 
the types of lipids they are exposed to (23, 24). CD1b and CD1c 
molecules traffic through and load lipids in the late endosome 
and the lysosome, and thus, are exposed to a low pH that may 
facilitate lipid exchange (25). However, CD1a molecules are unique 
in that under steady-state conditions, they do not accumulate or 
traffic through the late endosomes or lysosomes, and thus, are not 
exposed to the same low pH conditions as CD1b and -c molecules 
(26). Instead, modeling simulations suggest that CD1a molecules 
can be stably expressed on the cell surface in the absence of loaded 
lipid antigens (27), and other studies have shown that the CD1a 
binding groove can be stabilized by exogenously added lipids after 
being expressed on the cell surface (28).
Group 1 CD1 molecules present both microbial and self-lipid 
antigens to T cells. Historically, microbial antigens that were found 
to bind to group 1 CD1 molecules were derived from the cell wall of 
Mycobacteria species. Below, we will describe how the various group 
1 CD1 molecules interact with different types of lipids, and what 
some of the functional consequences for T cell activation might be.
Lipid Antigen Presentation by CD1a
CD1a molecules can bind the mycobacterial lipopeptide dide-
hydroxymycobactin (DDM), a biosynthetic precursor of the 
iron-chelating siderophore mycobactin, which is essential for 
Mtb growth within macrophages (29). CD1a presentation of 
DDM and subsequent TCR recognition of antigen have features 
reminiscent of both CD1 and MHC-like binding modes in that the 
CD1a-restricted TCR is capable of responding in an amino-acid 
sequence-specific manner to the solvent-exposed portion of the 
DDM lipopeptide (30). DDM-specific CD1a-restricted T cells were 
found to secrete varying levels of IL-2 in response to different 
synthetic DDM analogs, with the largest amount of IL-2 being 
produced when the DDM antigen was in its native state (31). This 
showed that CD1a-restricted T cells could specifically respond to 
the structural components of an antigen that are responsible for 
virulence (31).
The crystal structure of CD1a–DDM complex showed that 
A′ pocket of CD1a antigen-binding groove binds alkyl chains of 
discrete length, while the F′ pocket is less rigid and allows for 
different chemical head groups of lipid antigens to protrude from 
the groove (30). The crystal structure of CD1a with the bound 
self-antigen sulfatide provides another example of this type of 
binding mode wherein the sphingosine fits into the A′ pocket 
and the polar headgroup of sulfatide protrudes from the middle of 
the groove, allowing for optimal TCR recognition (32). However, 
despite the body of work showing that CD1a lipid antigens gener-
ally contain protruding polar headgroups and hydrophobic tails, 
a recent study showed that CD1a molecules could also bind and 
present “headless” lipid antigens to T cells (33). In fact, synthetic 
squalene, a lipid containing no headgroup, was able to activate the 
BC2 CD1a-restricted T cell line to the same extent as what was 
seen from challenge with sebaceous gland extract containing a 
mixture of CD1a autoantigens (33). This suggests that CD1a has 
the ability to recognize “headless” lipid antigens that lack a polar 
moiety available to be recognized by the TCR. A recent finding 
by Rossjohn’s group provided a potential explanation for this 
(34). This study first solved the crystal structure of a TCR bound 
to CD1a and mechanistically showed that the TCR can directly 
contact CD1a in the absence of lipid interaction. This interaction 
is sufficient for T cell activation. However, if CD1a is loaded with 
non-permissive lipids, there is a disruption of the TCR–CD1a 
docking site (34). Therefore, CD1a autoreactivity can result from 
direct contact of the TCR with CD1a, but only when the surface 
of CD1a is not disrupted by non-permissive ligands. Furthermore, 
a recent study showed that bee venom-derived phospholipase 2 
could activate CD1a-autoreactive T cells through the generation of 
small neo-antigens, such as free fatty acids and lysophopholipids, 
from common phosphodiacyl glycerides (35). This finding pro-
vides a potential mechanism underlying phospholipase-dependent 
inflammatory skin disease.
Lipid Antigen Presentation by CD1b
CD1b has the largest antigen-binding groove among the CD1 
proteins described to date. As such, CD1b binds and presents the 
most diverse array of mycobacterial lipids, which include mycolic 
acid (36), glucose monomycolate (GMM) (37), glycerol mono-
mycolate (38), phosphatidylinositol mannosides (PIMs) (39, 40), 
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lipoarabinomannans (LAM) (41–43), and sulfoglycolipids (44). 
The CD1b binding groove is composed of four interconnected 
pockets, which enable binding of the long hydrophobic tails of lipid 
antigens (45). The structure of CD1b–GMM complex showed that 
the A′, C′, F′, and T′ pockets in the CD1b binding groove form 
a deep “maze” that allows them to present large mycobacterial 
lipid antigens to T cells, and the close association of lipid ligands 
with CD1b molecules is suggestive of this complex having a long 
half-life (45). These studies also show that the pleiotropic binding 
of structurally diverse lipids to CD1b molecules can occur due to 
critical amino-acid residues in the CD1b binding groove having 
the ability to change their conformation to induce a tighter fit for 
different lipids (45, 46). However, the finding that CD1b molecules 
bind and are stabilized by such large microbial lipid ligands led 
to the question of how unloaded CD1b molecules retain their 
structure in the absence of endosomally loaded lipid. Operating 
from the hypothesis that endogenous self-lipids could act as 
stabilizers of the Ag-binding groove for CD1b in the absence of 
foreign ligands, Garcia-Alles et al. showed that CD1b associates 
with phosphatidylcholine (PC) and a long 40+ carbon spacer 
molecule prior to endosomal lipid loading (47). The combined 
number of carbons shared between PC and the spacer molecule 
is greater than the C65–C70 capacity of the CD1b binding groove, 
but this “overloading” of the groove may actually facilitate lipid 
exchange in the endolysosome (47).
Mycolic acids were the first CD1b-restricted lipids identified 
(36). Mycolic acids are the major Mtb cell wall lipid components 
and are crucial for Mtb virulence (48). Studies in untreated 
human Mtb patients showed that many patients contained IFN-γ 
producing, mycolic acid-specific CD1b-restricted T cells in their 
PBMCs (49), suggesting that mycolic acids are immunodominant 
CD1b-restricted antigens relevant during Mtb infection. While free 
mycolic acids can activate some CD1b-restricted T cells; one recent 
study suggested that mycolic acids may act as scaffolds for other 
lipid antigens, with the tight association of the long hydrophobic 
tails in the CD1b binding pockets leading to proper positioning 
of various lipid antigenic headgroup for TCR recognition (38).
Diacylated sulfoglycolipids (Ac2SGL) are produced by virulent 
Mtb strains upon infection of the human host (44, 50). Studies 
using human CD1b-restricted T cell lines specific for Ac2SGL 
showed that the aliphatic tail region is responsible for anchoring 
the molecule deep in the CD1b antigen-binding groove, while 
the trehalose headgroup is responsible for TCR recognition (50). 
However, the antigen specificity of particular T cell lines could be 
influenced by the length and isomerization of the hydrophobic 
tail region of Ac2SGL (50). This corroborates the study described 
above, which showed that the long hydrophobic lipid tails of CD1b 
lipid antigens, including Ac2SGLs, can act to position the antigenic 
headgroups optimally for TCR recognition (38, 47).
Mycobacterium tuberculosis PIMs and their polyglycosylated 
extensions lipomannans (LM) and LAM (51) are components 
of the Mtb cell envelope (52). Many forms of LM and LAM are 
presented by CD1b (42, 43). Biochemical and functional char-
acterization of structurally diverse forms of LM showed that the 
pathogenic Mtb strain H37RV contained LM moieties with longer 
and more branched mannan polymer domains than those from the 
avirulent strain Mycobacterium smegmatis (43). Thus, it is possible 
that virulent Mtb strains evolved to use their LM lipids as immune 
evasion factors, as CD1b–LM complexes from H37Rv were less 
potent activators of CD1b-restricted T cell responses than those 
from M. smegmatis (43).
Lipid Antigen Presentation by CD1c
The only known Mtb antigen presented by CD1c is phosphomy-
coketide (PM), a lipid that contains a single fully saturated alkyl 
chain with methyl branches at every fourth carbon (53, 54). The 
production of Mtb mannose-1-β-phosphomycoketide (MPM) 
occurs via enzymatic catalysis by Pks12, which is only found in 
slow-growing pathogenic strains of Mtb (55), suggesting that MPM 
is a potential virulence factor in Mtb pathogenesis. Recent studies 
showed that PM, a putative biosynthetic precursor for MPM can 
also bind to CD1c and activate CD1c-restricted T cells (56).
CD1c molecules have a unique antigen-binding mode that 
allows for presentation of diverse antigens, such as highly branched 
lipid species to T cells (57). Whereas lipid antigens bind in both the 
A′ and F′ pockets in CD1a and CD1b molecules (32, 45), MPM 
binds only to the A′ pocket in CD1c molecules, allowing for the 
branched side chains to protrude out from the groove (57). Like 
CD1a, CD1c can also present lipopeptide antigens to T cells (58). 
In addition, CD1c has been shown to bind sulfatide and other 
diacylated lipids similar to CD1a and CD1b (50, 59), suggesting 
that the CD1c binding groove has evolved to present a diverse 
array of lipid species.
A recent paper also helped shed light on a potential role for 
autoreactive CD1c-restricted T cells (22). Autoreactive CD1c-
restricted T cells were found to recognize methyl-lysophosphotidic 
acid, a novel class of self-lipids, which accumulate in leukemia 
cells (22). While these autoreactive CD1c-restricted T cells 
poorly recognize non-tumor CD1c-expressing cells, they killed 
CD1c+ acute leukemia cells and protected immunodeficient mice 
against CD1c+ human leukemia cells (22). This study suggests that 
autoreactive CD1c-restricted T cells may play a role in anti-tumor 
immunity (22). However, their role in anti-microbial immunity 
remains unknown.
Kinetics, Phenotype, and Unique 
Properties of Group 1 CD1-Restricted 
T Cells
Much of the information about group 1 CD1-restricted T cells 
comes from in  vitro assays using human T cell clones. Recent 
discoveries in tetramer development and improved cell isolation 
technology have greatly enhanced the study of group 1 CD1 
molecules in humans, though animal models are critical to fully 
understand the dynamic biology of group 1 CD1-restricted T cells. 
A recent study using rhesus macaques identified a GMM-specific 
T cell population in BCG-immunized monkeys (60). However, 
unlike humans, GMM-specific T cells were found to be CD1c 
restricted (61). Though interesting, following up on such find-
ings in primates can be challenging due to cost constraints. As an 
alternative to studying non-human primates, small animal models 
using transgenic mice have proven invaluable for the study of 
group 1 CD1-restricted T cells. In the following sections, we will 
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review recent discoveries about group 1 CD1-restricted T cells 
and the role they play in host immunity in vivo.
Small Animal Models to Study the In Vivo 
Function of Group 1 CD1-Restricted T Cells
There have been a number of small animal models used to study the 
in vivo function of group 1 CD1-restricted T cell responses during 
Mtb infection, including the guinea pig model and humanized 
mouse model. Based on comparison with human CD1 isoforms, 
the nine guinea pig CD1 genes encode four CD1b-like, three 
CD1c-like, one CD1d-like, and one CD1e-like molecule (2, 
62). Immunization of guinea pig with mycobacterial lipids has 
been shown to elicit antigen-specific proliferation and cytolytic 
capacity of group 1 CD1-restricted T cells (63). In addition, Mtb 
lipid-vaccinated guinea pigs exhibit reduced lung pathology after 
subsequent Mtb challenge (64). However, it has been difficult to 
show that group 1 CD1-restricted T cells mediate these protective 
effects due to limited experimental tools and reagents. Moreover, 
guinea pigs lack CD1a and have multiple isoforms of the CD1b 
and CD1c genes, suggesting that the group 1 CD1-restricted T cells 
response may be different in guinea pigs and humans.
A humanized mouse model developed by Gumperz’s group 
was observed to develop a functional CD1 compartment (6). This 
model involved grafting immunodeficient mice with human fetal 
thymus, liver, and CD34+ hematopoietic stem cells (6). While these 
mice were observed to express group 1 CD1 molecules, CD1a 
tissue expression patterns differed from humans (6). For instance, 
CD1a-expressing cells, which are normally abundant in human 
skin, are largely absent in humanized mice. It remains to be seen 
whether group 1 CD1-restrcited T cell responses can be elicited 
in these humanized mice upon immunization or during infection.
A transgenic mouse model that expresses the human group 1 
CD1 genes under their endogenous human promoters has been 
generated (4). Human group 1 CD1 transgenic (hCD1Tg) mice 
express CD1a, CD1b, and CD1c in a pattern similar to that seen in 
humans and support the development of group 1 CD1-restricted 
T cells (4). These T cells from hCD1Tg mice also share many 
phenotypic and functional characteristics with CD1-restricted T 
cells found in humans (4). These data demonstrate the viability of 
hCD1Tg mice as an animal model to study the in vivo function of 
group 1 CD1-restricted T cells. Indeed, both infection with Mtb 
and immunization with Mtb lipids elicit group 1 CD1-restricted 
T cell responses in hCD1Tg mice (4).
Group 1 CD1-Restricted T Cell Responses 
During Mtb infection
The presentation of mycobacterial lipid antigens by group 1 
CD1 molecules has been well characterized. However, our 
understanding of the phenotype and function of responding 
T cells was mostly limited to in vitro assays with T cell clones 
until recently. Nevertheless, in vitro studies have demonstrated 
that group 1 CD1-restricted T cells are cytotoxic and produce 
IFN-γ and TNF-α upon encountering mycobacterial antigens 
(65, 66). Moreover, group 1 CD1-restricted Mtb lipid antigen-
specific T cells are found in higher frequencies in individuals 
exposed to Mtb compared with a control population, suggesting 
that Mtb-specific CD1-restricted T cells are activated following 
infection with Mtb (38, 44, 65–67). The discovery of CD1-
tetramer technology has made it easier to study T cell reactivity 
by enabling the direct isolation of antigen-specific T cells from 
the blood and tissue (56, 68). Moreover, the establishment of a 
group 1 CD1 transgenic mouse model has enabled the study of 
tissue distribution, activation kinetics, and phenotype of group 
1 CD1-restricted T cells.
CD1a dextramers loaded with the mycobacterial lipopeptide 
DDM stained CD1a-restricted T cells in individuals with active TB 
and tuberculin-positive individuals, suggesting an expansion had 
occurred upon exposure to Mtb (69). CD1a/DDM dextramer+ T 
cells were found to be either CD4+ or CD8+, and produced IFN-γ 
and TNF-α in response to CD1a-expressing APCs treated with 
DDM. Studies with CD1b/GMM tetramers revealed the expansion 
of CD1b/GMM-specific T cells in individuals infected with Mtb, 
but not healthy individuals (68). These cells were found to be CD4+ 
TCRαβ+ and appeared to have a conserved TCR repertoire. CD1b/
GMM-specific T cells were later separated into two types based 
on their avidity to CD1b/GMM. GMM-specific T cells with a 
high avidity to CD1b/GMM termed GEM (Germline-encoded, 
mycolyl-reactive) T cells expressed highly conserved TCRs com-
posed of a TRAV1-2 (Vα 7.2) V segment rearranged with TRAJ9, 
with limited CDR3α diversity (70). GEM T cells were found at a 
very low frequency in Mtb naïve individuals. A second population 
with an intermediate avidity to CD1b/GMM was also observed 
and this population showed diverse TCR usage (71). Recently, 
Moody and colleagues described that CD1c-restricted T cells 
respond to glycosylated and unglycosylated forms of mycoketide 
presented by DCs or B cells (56). However, in cell-free systems, 
CD1c-restricted T cells responded only to unglycosylated forms 
of mycoketide (PM). Moreover, PM-loaded CD1c tetramers could 
detect antigen-specific T cells from PBMC of donors with latent 
TB. A comprehensive molecular analysis of TCR recognition of 
CD1c-mediated PM/MPM presentation revealed that some T cell 
clones recognize both PM and MPM while others are specific to 
either PM or MPM (72).
Studies infecting group 1 CD1-expressing hCD1Tg mice with 
BCG or Mtb revealed that the kinetics of group 1 CD1-restricted T 
cell responses were different from group 2 CD1d-restricted iNKT 
cells (4). Group 1 CD1-restricted T cells were detected at week 3 
or 4 post infection, suggesting that they follow similar activation 
kinetics as peptide-specific conventional T cells. This study pro-
vided the first direct in vivo evidence that group 1 CD1-restricted 
T cell responses are induced by Mtb infection (4). Immunizing 
mice with BMDCs pulsed with Mtb lipid antigens followed by 
secondary challenge accelerated group 1 CD1-restricted T cell 
responses, indicating that group 1 CD1-restricted T cells can 
mount a memory response (4). Taken together, these studies 
support the potential use of group 1 CD1-restricted Mtb lipid 
antigens as components of subunit vaccines.
Autoreactive Group 1 CD1-Restricted T Cells
Early reports of T cell recognition of group 1 CD1 molecules sug-
gested that many CD1-restricted T cells are autoreactive (73, 74). 
A recent analysis of T cell clones from human PBMC showed that 
CD1a self-reactive T cells are present at high frequencies in the 
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blood of healthy individuals (75). CD1a-restricted autoreactive T 
cells expressed diverse TCRs and skin homing receptors CCR4, 
CCR6, CCR10, and secreted IL-22. Given the properties of CD1a-
autoreactive T cells and the fact that CD1a recognizes skin lipid 
antigens and is highly expressed on Langerhans cells implies that 
these T cells play a role in dermal immunity (33, 75). Another study 
investigated that the frequency and effector phenotype of autoreac-
tive group 1 CD1-restricted T cells in human blood and cord blood 
using C1R transfectants expressing CD1a, CD1b, and CD1c (76). 
They found that the frequencies of group 1 CD1 autoreactive T 
cells were in the range of 1/10–1/300 circulating T cells. CD1a- and 
CD1c-restricted T cells comprised the most abundant autoreactive 
T cells. These group 1 CD1 autoreactive T cells had a diverse phe-
notype and exhibited mostly Th1 and Th0 functional activities (76).
Most of the CTLs derived from hCD1Tg mice are autoreactive 
(4). While the endogenous lipid antigens that activate these CTLs 
were not identified in this study, these clones were found to lyse 
hCD1Tg DC and group 1 CD1-expressing cells from humans. 
This suggests that the self-antigens recognized by these CTLs are 
conserved between mice and humans. Autoreactive T cells can also 
be detected from Mtb-infected mice. A transgenic mouse model, 
HJ1Tg, expressing an autoreactive CD1b-restricted TCR has been 
generated to study the development and function of group 1 CD1 
autoreactive T cells (5). Similar to CD1d-restricted iNKT cells, HJ1 
T cells exhibited an activated phenotype (CD44+CD69+CD122+) 
and a subset of HJ1 T cells expressed NK1.1 and was enriched in 
the liver (5). This finding raises the possibility that autoreactive 
group 1 CD1-restricted T cells may also reside within the NKT cell 
compartment of the human liver. HJ1 T cells were cytolytic and 
secreted proinflammatory cytokines (IFN-γ, IL-17A, and TNF-α) 
in response to CD1b-expressing DCs. TLR agonists (Pam3Cys and 
LPS) enhanced the autoreactivity of HJ1 T cells by stimulating DCs 
to produce IL12/IL23. Furthermore, HJ1 T cells were activated 
early during Listeria infection and played an immunoprotective 
role (5). The potential role of group 1 CD1 autoreactive T cells in 
other infections remains to be defined.
Developmental Requirements of Group 1  
CD1-Restricted T Cells
The development of group 1 CD1-restricted T cells has not been 
well-studied due to a lack of a suitable small animal model, but 
some progress has been made in this regard. Studies using HJ1Tg 
mice showed that CD1b-expressing hematopoietic cells are neces-
sary and sufficient to mediate the positive selection of HJ1 T cells 
(5). Cortical thymocytes are most likely the main cell type involved 
in the selection of HJ1 T cells as CD1b is not expressed on mature 
thymocytes. HJ1 T cells that developed in the hCD1Tg background 
expressed similar levels of the transcription factor PLZF as iNKT 
cells. PLZF is expressed by several non-conventional T cell subsets 
that display an activated phenotype and is responsible for their 
innate-like effector program (77–80). However, studies of group 1 
CD1 autoreactive T cells in humans showed that autoreactive group 
1 CD1-restricted T cells were present in both naive (CD45RA+) 
and effector/memory (CD45RO+) compartments (75, 76). It is 
unclear whether TCR–CD1 avidity and the nature of the selecting 
lipid antigen(s) may play a role in determining the phenotype of 
group 1 CD1 autoreactive T cells. Moreover, the developmental 
selection program for microbial lipid antigen-specific group 1 
CD1-restricted T cells has not yet been investigated.
Group 1 vs. Group 2 CD1-Restricted T 
Cells: Some Similarities, Many Differences
Group 1 and group 2 CD1 molecules share many similarities 
beyond the presentation of lipid antigens to T cells, including 
molecular assembly mechanisms and sharing self-lipid moieties 
that stabilize the CD1 binding groove in the absence of foreign 
antigen (81, 82). However, many differences also exist regarding 
the functional capacity of their cognate T cells and APC–T cell 
interactions. The following sections will focus on comparing and 
contrasting group 1 and group 2 CD1-restricted T cells in terms of 
TCR diversity, lipid recognition, cytokine production, and APC–T 
cell interactions. Table 1 highlights the properties of these two 
groups of CD1-restricted T cells.
TCR Diversity in CD1-Restricted T Cells
CD1d-restricted NKT cells can be divided into two subsets based on 
TCR diversity (83). Type I NKT cells, also known as invariant NKT 
(iNKT) cells, express an invariant TCR α chain. Murine type I NKT 
cells express an invariant Vα14–Jα18 TCR α chain paired with a 
limited set of TCR β chains, including Vβ8.2, Vβ7, and Vβ2 (83). Like 
murine type I NKT cells, human type I NKT cells express the invariant 
Vα24–Jα18 TCR α chain paired with predominantly the Vβ11 chain 
(84). All type I NKT cells recognize the marine sponge-derived gly-
colipid, α-galactosylceramide (α-GalCer) (85). Other populations of 
CD1d-restricted NKT cells that respond to lipid antigens are broadly 
classified as type II NKT cells, which exhibit more TCR sequence 
diversity compared to type I NKT cells (86). Type II NKT cells do 
not respond to α-GalCer, and therefore, cannot be identified using 
α-GalCer/CD1d tetramers (86). Several studies have suggested that 
group 1 CD1-restricted T cells have diverse TCR usage (4, 33, 74, 76). 
However, CD1b-restricted GEM T cells were recently described to 
express highly conserved TCRs composed of a TRAV1-2V segment 
rearranged with TRAJ9, with limited CDR3α diversity (70).
Lipid Antigen Recognition by Group 1 and 
Group 2 CD1-Restricted T Cells
Both group 1 and group 2 CD1 have been shown to present self-lipid 
antigens to CD1 autoreactive T cells. However, each member of the 
CD1 family binds distinct self-lipids. CD1d binds to sphingomy-
elin, gangliosides (e.g., GD3), globo/isoglobosides, phospholipids, 
plasmalogens, and lysophospholipids (82, 87–93). However, it 
remains unclear which of these lipids stimulate iNKT cells under 
physiological conditions and which contribute to the activation 
of iNKT cells during microbial infection (94). Gangliosides (e.g., 
GM1, GD1) were also described to bind to CD1b and activate 
CD1b-restricted T cells (95). Diacylglycerophosphocholines 
and diacylglycerophoshoinositol were shown to be bound by 
CD1c (87). However, it is unclear whether these self-lipids can 
be recognized by CD1c-restricted T cells. Self-lipids bound by 
CD1a molecules include squalene, wax esters, and triacylglycerides 
derived from the skin (33). Interestingly, sulfatide can bind to all 
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group 1 and group 2 CD1 proteins (CD1a, CD1b, CD1c, CD1d) 
and activate CD1-restricted T cells (59, 96).
Most studies examining microbial antigen presentation by group 
1 CD1 molecules have focused on Mtb, but CD1d-restricted iNKT 
cells have been shown to bind microbial antigens from a variety of 
pathogens. Both CD1d and CD1b molecules bind and present PIM 
moieties from Mtb, though they bind different isoforms (40, 97). 
In addition, diacylglycerol lipid species from pathogens including 
B. burgdorferi and Streptococcus pneumoniae have been identified 
as CD1d-restricted iNKT cell ligands, with physiologically relevant 
effects on T cell responses during infection (98, 99). No comparable 
diversity in microbial ligands has been shown to exist in group 1 
CD1-mediated antigen presentation. However, the biochemical 
nature of the group 1 CD1 antigen-binding groove suggests that 
diverse microbial antigens can be presented.
effector Functions of Group 1 and Group 2 
CD1-Restricted T Cells
Group 1 and group 2 CD1-restricted T cells display antigen-specific 
cytotoxicity in the context of sterile cancer and infectious disease. 
Like group 1 CD1 autoreactive T cells, type I and type II NKT cells 
are capable of directly lysing tumor cells (100–103). Upon activation, 
type I NKT cells can produce both Th1 (IFN-γ, TNF-α) and Th2 (IL-
4, IL-5, IL-13) cytokines, and this dual functionality enables them to 
play both pathogenic and immunoregulatory roles in various disease 
settings (104). Type I NKT cells were also shown to produce anti-
inflammatory cytokines, such as IL-10 and TGF-β. Similar to type I 
NKT cells, type II NKT cells are also capable of producing multiple 
cytokines in response to polyclonal TCR stimulation, including IFN-
γ, IL-4, GM-CSF, and IL-13 (105). These findings show that group 
2 CD1-restricted NKT cells can produce a variety of Th1, Th2, and 
regulatory cytokines in response to different environmental cues.
Group 1 CD1-restricted T cells have also been shown to produce 
multiple cytokines in the context of infection, inflammation, and 
TABLe 1 | Comparison of group 1 and group 2 CD1-restricted T cells.
Group 1 CD1-restricted T cells Group 2 CD1-restricted T cells
Types Microbial antigen-specific Autoreactive Type I (iNKT) Type II (vNKT)
Retricted by CD1a, CD1b, CD1c CD1d
Antigens recognized Mtb lipid antigens CD1a – squalene, wax esters, 
triacylglycerides, sulfatide
α-GalCer analogs, 
glycosphingolipids, α-Gal-
diacylglycerols, phospholipids, 
gangliosides, isoglobosides
β-GluCer, sulfatide, 
lysosulfatide, 
lysophospholipidsCD1b – gangliosides, sulfatide
CD1c – methy-lysophosphatidic acid, sulfatide
Antigen capture CD1a – cell surface and early endosomes Endosomes and lysosomes
CD1b – late endosomes and lysosomes
CD1c – endosomes
Cell type that mediates selection Unknown Hematopoietic cells Hematopoietic cells
Subset CD4+, CD8+, DN CD4+, CD8+, DN Human-CD4+, CD8+, DN 
Mouse-CD4+, DN
CD4+, CD8+, DN
TCR usage Diverse TCRαβ chains,  
Vα7.2-Jα9 (GEM T cells)
Diverse TCRαβ chains Human – Vα24- Diverse TCRαβ 
chains (mouse – 
Vα3.2, Vα8, Vβ8 
bias)
Jα18; Vβ11
Mouse – Vα14-
Jα18; Vβ8.2, Vβ7, Vβ2,
Effector functions Cytotoxic, produce  
IFNγ, TNFα
Cytotoxic, produce IFNγ, TNFα, IL-17 Cytotoxic, produce Th1, Th2, 
Th17 cytokines
Cytotoxic, produce 
Th1, Th2 cytokines
cancer. Autoreactive group 1 CD1-restricted T cell lines produce 
IFN-γ, TNF-α, IL-17, and IL-22 in response to self-antigenic 
stimulation (5). Both in vitro and in vivo assays demonstrated that 
group 1 CD1-restricted T cells produce IFN-γ and TNF-α upon 
encountering mycobacterial antigens (4, 65, 66). Unlike group 2 
CD1-restricted T cells, most group 1 CD1-restricted T cells do not 
appear to produce Th2 and/or regulatory cytokines in response to 
antigenic stimulation. However, to date, all the studies examining 
group 1 CD1-restricted T cells do so in Mtb infection settings. 
Further experiments need to be conducted to ascertain whether 
group 1 CD1-restricted T cells produce Th2 and/or regulatory 
cytokines under other infectious or inflammatory conditions.
Antigen-Presenting Cell–T Cell interactions
Although all APCs expressing CD1d have the potential to present 
lipid antigens to NKT cells, studies depleting specific types of APCs 
have revealed that APC subsets differ in their capacity to prime type 
I NKT cells with lipid antigens (106). A recent study demonstrated 
that CD8α+ DEC-205+ dendritic cells were the main cell type 
responsible for capturing and presenting multiple forms of α-GalCer 
and stimulated type I NKT cell responses in vivo (106). However, it is 
unclear which APC subset is responsible for presenting Mtb antigens 
to group 1 CD1-restricted T cells in vivo. Macrophages are the pri-
mary host cells for Mtb but do not express group 1 CD1 molecules. 
It was demonstrated that group 1 CD1-expressing DCs take up 
apoptotic vesicles from bystander infected cells and presented them 
to human CD8+ T cells in an in vitro co-culture experiment (107). 
Thus, group 1 CD1-expressing DCs may similarly cross-present Mtb 
lipid antigens to T cells during infection (Figure 1).
Most of the studies involving CD1d have been performed in 
murine models. However, as humans possess both group 1 CD1 
and group 2 CD1 molecules, it is possible that presence of group 1 
CD1 molecules may affect CD1d antigen presentation. While there 
is some specialization in the antigen presentation functions of CD1 
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molecules, whereby they sample lipids from different intracellular 
compartments, sulfatide, a glycosphingolipid, is capable of promis-
cuously binding to CD1a, CD1b, CD1c, and CD1d (59). As CD1c 
tends to be co-expressed with CD1d on blood dendritic cells and a 
fraction of B cells, a recent study evaluated how the presence of CD1c 
influences the activation of CD1d-restricted iNKT cells (108). This 
study demonstrated that CD1c is able to present α-GalCer as a weak 
agonist to human iNKT cells, and the presence of CD1c enhances 
α-GalCer-dependent activation of iNKT cells by CD1d (108).
Role of Group 1 and Group 2 CD1-Restricted 
T Cells During infection
The studies described above support the likely role of group 1 
CD1-restricted T cells in protective immunity against Mtb infec-
tion. However, the mechanisms by which they control Mtb infec-
tion remain to be elucidated. Aside from Mtb, the role of group 1 
CD1-restricted T cells in other microbial infection has not been 
addressed. In contrast, the role of CD1d-restricted iNKT cells in 
host defense against various pathogens has been  extensively studied 
(109). Studies examining iNKT cell dynamics in mice infected intra-
venously with BCG showed an early expansion of iNKT cells in the 
lung with a peak at day 8 after infection, followed by a subsequent 
decline likely due to programed cell death (110, 111). Other studies 
have suggested that iNKT cells may play a role in the formation of 
granulomas in response to mycobacterial cell wall components (112, 
113). Furthermore, in vitro experiments have shown that iNKT cells 
possess the ability to kill Mtb-infected APCs through the production 
FiGURe 1 | Group 1 CD1-restricted T cells consist of autoreactive and 
microbial antigen-specific T cells. Microbial lipid-specific T cells are 
activated by microbial lipids that are loaded on group 1 CD1 molecules. 
Autoreactive T cells are activated in combination by proinflammatory 
cytokines produced on TLR engagement and self-lipid antigens. During Mtb 
infection, group 1 CD1-expressing DCs can either be directly infected by Mtb 
or take up apoptotic vesicles from bystander infected cells and present 
Mtb-derived antigens to group 1 CD1-restricted Mtb lipid-specific T cells. 
Activated group 1 CD1-restricted T cells are cytotoxic and can directly lyse 
Mtb-infected cells. Activated group 1 CD1-restricted T cells also produce 
IFN-γ and TNF-α, which can activate infected macrophages and help to 
control Mtb growth.
of GM-CSF (114). However, Mtb infection of CD1d−/− or Jα18−/− 
mice with Mtb resulted in no significant difference in mortality or 
bacterial burdens in the lung, suggesting that iNKT cells may play 
a redundant role in the control of Mtb (115–117).
Conclusion
We highlight several recent studies that have contributed to our 
understanding of group 1 CD1 antigen presentation and the role 
group 1 CD1-restricted T cells play during Mtb infection. Further 
studies are needed to characterize Mtb lipid-specific T cell memory 
responses and evaluate whether Mtb lipid antigens can effectively 
be used in a subunit vaccine. Future studies also need to expand 
on the role of autoreactive group 1 CD1-restricted T cells in Mtb 
infections, as it is unknown whether they have similar activation 
kinetics as antigen-specific T cells and how they affect host immu-
nity to infection. Moreover, it remains unclear whether group 1 
CD1 molecules present lipids from other microbial species and 
whether they play a role in other inflammatory diseases, presenting 
fertile ground for future investigation.
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